RxDoctor Payments Data

Jennifer Lockard

Primary Care · Toledo, OHNPI 1750865887

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 26.4% of the total. Reporting peaked in 2024 at $100 and has fallen 65.5% since, to $35 in 2025. That places this record below the midpoint for primary care clinicians in OH, where the typical reported total is $373.

$281in general payments, 2019–2025

Across 11 payments — averaging $25.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$74
  • Otsuka America Pharmaceutical, Inc.$65
  • SK Life Science, Inc.$36
  • Intuitive Surgical$35
  • Lundbeck LLC$23
  • Johnson & Johnson$20
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$281100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$281 in reported general payments places this provider in the 40th percentile of 321 primary care providers in Ohio.

See all primary care providers in Ohio →

Medicare billing

Part B allowed, 2024
$65,667
Medicare patients
189
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$27,643
TrulicityDulaglutide29$16,276
FarxigaDapagliflozin Propanediol22$13,068
JardianceEmpagliflozin28$12,163
XareltoRivaroxaban17$9,382
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog42$7,640
MyrbetriqMirabegron16$7,466
EntrestoSacubitril/Valsartan21$6,749
Fentanyl27$4,022
Lantus SolostarInsulin Glargine,hum.Rec.Anlog78$3,031
Pregabalin27$2,489
Mirtazapine79$2,376
Lacosamide21$2,116
Atorvastatin Calcium154$1,971
Bumetanide53$1,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$20$9,38217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 321 primary care providers in Ohio.

Other primary care in Toledo

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →